Welcome to the Savara Conference Call. At this time, all participants are in listen-only mode. An audio webcast of this call will be available on the Investors section of Savara's website at savarapharma.com. This call is subject to copyright and is the property of Savara. All recordings, reproduction or transmission of this call without the expressed written consent of Savara is strictly prohibited. As a reminder, today's call is being recorded.
I would now like to turn the phone over to Anne Erickson, Head of Investor Relations and Corporate Communications at Savara. Good afternoon and thank you for joining us today. A press release reporting our fourth quarter, end of year 2019 financial results was issued earlier today, March 12th, 2020, and can be found on the Investors section of our website at savarapharma.com. If you've not received this release or if you'd like to be added to the company's distribution list, please e-mail me at firstname.lastname@example.org. This call is also being webcast live. And approximately one hour after the call, a replay will be available on the company's website and will remain available for the next 30 days. A telephone replay will also be available through March 19. Please note that today's conference call and webcast contain forward-looking statements within the meaning of federal securities laws, including statements regarding the company's strategy, goals, product candidates, clinical studies and financing matters. Such statements are subject to significant risks and uncertainties, including those described in our press release issued today, Thursday, March 12th, 2020, and our recent SEC filings on Forms 8-K, 10-K and 10-Q. Actual results or performance may differ materially from expectations indicated by our forward-looking statements due to those risks and uncertainties. We caution you to not place undue reliance on any of the forward-looking statements, which speak only as of today. As usual, we'll take analyst questions at the end of the call. However, we also encourage shareholders to submit questions by e-mail to email@example.com. Time permitting, we will address these questions alongside any others received. Joining me on the call today are Rob Neville, Chief Executive Officer; Badrul Chowdhury, Chief Medical Officer; Taneli Jouhikainen, President and Chief Operating Officer; and Dave Lowrance, Chief Financial Officer. I'll now turn the call over to Rob.
Well, thank you, Anne. Good afternoon, everybody, and welcome to our fourth quarter and year-end call. I do appreciate you joining us. And today, we will provide a recap of the last quarter and summarize results we just announced today from clinical studies in Molgradex, including positive data from the open-label period of IMPALA study that showed clinical outcomes was sustained or improved over a longer duration on drug. Finally, we'll share our plans for advancing our pipeline in 2020.
I am pleased to say, we ended 2019 with positive momentum. Notably, we secured additional financing by closing a private placement with total potential proceeds of up to $75 million. We strengthened our Board of Directors and executive leadership team; and announced Molgradex for
Chief Executive Officer
Chief Medical Officer
Chief Operating Officer
Chief Financial Officer
Vice President, Investor Relations and Corporate Communications
We are pleased that you like our content! Sign Up now to access premium content for free, a very limited time offer.
Welcome! Create your account
You are successfully registered!
An activation link has been sent to your mail. Please activate and login.